SteelPeak Wealth LLC Sells 169 Shares of Masimo Co. (NASDAQ:MASI)

SteelPeak Wealth LLC reduced its stake in shares of Masimo Co. (NASDAQ:MASI) by 4.0% in the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 4,105 shares of the medical equipment provider’s stock after selling 169 shares during the quarter. SteelPeak Wealth LLC’s holdings in Masimo were worth $679,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other institutional investors and hedge funds have also recently modified their holdings of the stock. FMR LLC grew its stake in Masimo by 41.2% during the third quarter. FMR LLC now owns 6,756,618 shares of the medical equipment provider’s stock valued at $900,860,000 after acquiring an additional 1,970,883 shares in the last quarter. State Street Corp increased its holdings in shares of Masimo by 0.7% in the third quarter. State Street Corp now owns 1,438,814 shares of the medical equipment provider’s stock worth $191,837,000 after purchasing an additional 10,179 shares during the last quarter. Westfield Capital Management Co. LP lifted its position in shares of Masimo by 23.2% in the third quarter. Westfield Capital Management Co. LP now owns 1,394,056 shares of the medical equipment provider’s stock worth $185,869,000 after buying an additional 262,370 shares in the last quarter. Geode Capital Management LLC boosted its stake in Masimo by 1.5% during the third quarter. Geode Capital Management LLC now owns 792,886 shares of the medical equipment provider’s stock valued at $105,741,000 after buying an additional 11,984 shares during the last quarter. Finally, Massachusetts Financial Services Co. MA grew its holdings in Masimo by 9.8% during the 3rd quarter. Massachusetts Financial Services Co. MA now owns 792,166 shares of the medical equipment provider’s stock valued at $105,619,000 after buying an additional 70,440 shares in the last quarter. Institutional investors own 85.96% of the company’s stock.

Analysts Set New Price Targets

Several brokerages recently weighed in on MASI. Wells Fargo & Company boosted their price target on shares of Masimo from $171.00 to $193.00 and gave the stock an “overweight” rating in a research report on Wednesday, December 11th. Piper Sandler boosted their price objective on Masimo from $180.00 to $210.00 and gave the stock an “overweight” rating in a research note on Wednesday, December 18th. Raymond James raised their price objective on Masimo from $170.00 to $194.00 and gave the company an “outperform” rating in a research note on Friday, December 27th. BTIG Research boosted their target price on Masimo from $166.00 to $170.00 and gave the company a “buy” rating in a research report on Monday, October 14th. Finally, Needham & Company LLC reaffirmed a “hold” rating on shares of Masimo in a research note on Wednesday, January 22nd. Two equities research analysts have rated the stock with a hold rating and five have assigned a buy rating to the company. According to MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $191.40.

Masimo Stock Up 2.3 %

Shares of MASI opened at $181.70 on Friday. The firm has a fifty day moving average price of $171.00 and a 200-day moving average price of $143.75. The company has a current ratio of 2.01, a quick ratio of 1.11 and a debt-to-equity ratio of 0.50. The firm has a market capitalization of $9.73 billion, a P/E ratio of 125.31 and a beta of 1.01. Masimo Co. has a 12-month low of $101.61 and a 12-month high of $183.14.

Masimo (NASDAQ:MASI) last issued its earnings results on Tuesday, November 5th. The medical equipment provider reported $0.98 EPS for the quarter, topping analysts’ consensus estimates of $0.84 by $0.14. Masimo had a net margin of 3.85% and a return on equity of 14.98%. The business had revenue of $504.60 million for the quarter, compared to the consensus estimate of $502.87 million. During the same period in the prior year, the firm earned $0.63 EPS. The company’s revenue for the quarter was up 5.4% compared to the same quarter last year. Equities research analysts expect that Masimo Co. will post 4.1 earnings per share for the current year.

Masimo Company Profile

Masimo Corporation develops, manufactures, and markets various patient monitoring technologies, and automation and connectivity solutions worldwide. The company offers masimo signal extraction technology (SET) pulse oximetry with measure-through motion and low perfusion pulse oximetry monitoring to address the primary limitations of conventional pulse oximetry; Masimo rainbow SET platform, including rainbow SET Pulse CO-Oximetry products that allows noninvasive monitoring of carboxyhemoglobin, methemoglobin, hemoglobin concentration, fractional arterial oxygen saturation, oxygen content, pleth variability index, rainbow pleth variability index, respiration rate from the pleth, and oxygen reserve index, as well as acoustic respiration monitoring, SedLine brain function monitoring, NomoLine capnography and gas monitoring, and regional oximetry.